How Real-World Data Is Driving Drug Label Expansion in Rare Diseases

Introduction: Why Real-World Data Matters in Rare Diseases

Rare disease clinical development is often limited by small patient populations, short trial durations, and narrowly defined eligibility criteria. This can result in regulatory approvals that are restrictive in scope—covering only a subset of patients or requiring specific biomarkers. Real-world data (RWD), collected from sources such as registries, electronic health records (EHRs), claims databases, and patient-reported outcomes, provides critical evidence to expand drug labels and make treatments accessible to broader patient groups.

Regulators like the FDA and EMA now increasingly rely on real-world evidence (RWE) to support post-marketing commitments, label modifications, and expanded indications. For rare diseases where randomized controlled trials (RCTs) are often not feasible, RWD bridges the gap between controlled environments and real-life clinical practice. It provides insights into long-term safety, effectiveness in heterogeneous populations, and comparative effectiveness across treatments.

Case Study: Spinal Muscular Atrophy (SMA) Label Expansion

An important example is the approval and subsequent label expansion of nusinersen for spinal muscular atrophy (SMA). Initially approved for pediatric populations based on limited RCT data, subsequent real-world registry studies demonstrated effectiveness in adult SMA patients. These data included improvements in motor function and survival benefits not captured in the original pivotal studies.

Through collaborative global registries and post-authorization safety studies, regulators accepted this evidence to expand the nusinersen label to include a wider range of SMA patients. This case highlights how structured data collection beyond the trial setting can influence regulatory decision-making and accelerate patient access.

Regulatory Pathways for Label Expansion Using RWD

Agencies like the FDA and EMA have issued guidance documents outlining how RWD can support regulatory submissions. Key pathways include:

• Supplemental New Drug Applications (sNDAs) supported by registry data or pragmatic trial results.
• Conditional approvals that rely on RWE to confirm benefit-risk in the post-marketing phase.
• Label expansions driven by long-term observational data demonstrating sustained benefit.

For example, in ultra-rare metabolic disorders, RWD from global patient registries has been used to show treatment benefits in real-life populations, supporting regulatory amendments to broaden eligibility criteria.

Challenges in Using RWD for Rare Diseases

Despite its promise, using RWD in rare diseases presents challenges:

• Data heterogeneity—different registries and hospitals may collect variables inconsistently.
• Missing data—due to limited follow-up or incomplete documentation in small cohorts.
• Biases—such as selection bias, since patients enrolled in registries may not represent the entire population.
• Regulatory acceptance—ensuring RWD meets the same standards of reliability and validity as clinical trial data.

Strategies like standardized data dictionaries, interoperable platforms, and common outcome measures are critical to overcoming these limitations.

Pragmatic Trials and Hybrid Designs

One way to strengthen RWD is through pragmatic and hybrid clinical trial designs. These studies integrate trial methodology with real-world practice, for example by recruiting patients from existing registries, using EHR-based randomization, or embedding follow-up assessments into routine care.

For rare diseases, such designs allow sponsors to capture robust evidence from small, dispersed populations while ensuring the data reflects real-world practice. Regulators increasingly recognize these models as valid sources of evidence for label expansions.

Role of Global Registries and Data Sharing

Global collaboration is essential. Rare disease registries like those supported by ClinicalTrials.gov and the European Rare Disease Registry Infrastructure enable multi-country data pooling. This harmonization allows sponsors to generate statistically meaningful evidence across geographies. It also facilitates comparative studies between drugs and across subgroups that would be impossible in isolated national cohorts.

For example, in rare oncology trials, multinational registries have been crucial in showing treatment effects in subtypes excluded from original pivotal studies. Regulators have then used this evidence to expand indications.

Future of RWD in Rare Disease Approvals

The future role of RWD in rare disease approvals will expand further with advances in:

• Digital health monitoring—wearable devices collecting continuous patient-level data.
• Artificial intelligence—analyzing unstructured EHR and claims data to detect rare disease outcomes.
• Blockchain technology—ensuring integrity and traceability of patient data for regulatory submissions.

As technology and regulatory science converge, RWD will not only supplement but sometimes replace traditional trial data for label expansion in small populations.

Conclusion

Real-world data is becoming indispensable in rare disease drug development and label expansion. By providing evidence on long-term safety, effectiveness across diverse populations, and patient-reported outcomes, RWD enables regulators to make informed decisions beyond the limits of small RCTs. The SMA case and numerous metabolic disorder approvals demonstrate how patient registries, EHR data, and pragmatic trials are transforming access to therapies for rare disease communities worldwide.